Almost all patients who are waiting for a regraft of a kidney transplant have anti-HLA antibodies

El‐Awar, Nadim; Terasaki, Paul I.; Lazda, Velta A.; Nikaein, Afzal; Manning, Carolina H.; Arnold, Angelo N.

doi:10.1016/s0041-1345(02)03520-0

Cited by 46 publications

(26 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It has been shown that nearly all patients who had rejected a renal allograft displayed anti-HLA alloantibodies [3,4]. The de novo development of anti-HLA alloantibodies in transplant recipients has been identified as a risk factor for both, acute and chronic rejection [5][6][7].…”

Section: Introductionmentioning

confidence: 99%

Detection and specification of noncomplement binding anti-HLA alloantibodies

Arnold

Zacher²,

Dechant

et al. 2004

Human Immunology

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Detection and specification of noncomplement binding anti-HLA alloantibodies

Arnold

Zacher²,

Dechant

et al. 2004

Human Immunology

View full text Add to dashboard Cite

“…11 In the early 1970s, Morris and Jeannette successively found that the antibody for the cause of the rejection was DSA. 12,13 With the further increase of the antibody detection technology, Harmer et al found that DSA was detected with flow cytometry technology in 95% of patients which showed rejection. 12 A large amount of specimen (826 cases of patients with organ rejection) research has shown that 96% of patients were detected DSA.…”

Section: Discussionmentioning

confidence: 99%

Influence ofde novodonor-specific antibody on early renal allograft function recovery

et al. 2015

View full text Add to dashboard Cite

showed acute rejection (AR) in 6 months after transplant. The HLA antibody-positive patients included six cases of dnDSA-positive and 60 cases of dnDSA-negative. The incidence of AR was 2.09% (5/239) in HLA antibody-negative patients, 18.33% (11/60) in HLA antibody positive with DSA-negative patients, and 83.33% (5/6) in HLA antibody-positive patients with DSA-positive. There was a big difference between DSA-negative and DSA-positive patients (p50.01). The recovery time of AR patients with DSA-positive were longer than DSA-negative patients, and the recovery graft function of AR patient with DSA-positive were not as good as those with DSA-negative. Conclusions: The appearance of dnDSA in the early stage of kidney transplantation is a warning sign of AR occurrence. Dynamic monitoring of HLA antibody and DSA could predict the state of graft function, and play an important role in the prevention of AR, timely and effectively.

show abstract

“…In addition, HLA antibodies are present in all patients who lost a previous graft and await revision transplant. 53 Antibodies against non-HLA antigens such as the angiotensin type 1 receptor may be present on graft endothelium, and this may impair graft outcome. 54 Highly sensitized patients (percent patients on waiting list: United States, 14%; Eurotransplant, 2%) have ≥ 85% serum panel reactive antibodies.…”

Section: Desensitizationmentioning

confidence: 99%

Induction Immunosuppressive Therapy in Kidney Transplantation

Bakr

Nagib²,

Donia³

2014

Exp Clin Transplant

View full text Add to dashboard Cite

Induction therapy after kidney transplantation is intensive immunosuppression in the initial days after transplant when the immune system of the recipient has the first contact with donor antigens. Initial intensive immunosuppression may be required to prevent acute rejection and graft loss, and subsequent immuno-suppression may be decreased to minimize adverse events associated with immunosuppressive drugs. Induction agents include lymphocyte-depleting antibodies such as rabbit antithymocyte globulin, alemtuzumab, muromonab-CD3, rituximab, and bortezomib; lymphocytenondepleting antibodies such as interleukin 2 receptor antibodies; and other discontinued or investigational agents such as efalizumab and alefacept. Induction therapy may be adjusted for special situations such as living-donor kidney transplant, pediatric transplant, hepatitis C virusseropositive recipients, recipients who require desensitization, patients who are at risk for developing delayed graft function, and old donors. The optimal immunosuppressive regimen may vary, and clinical practice guidelines are available.

show abstract

Almost all patients who are waiting for a regraft of a kidney transplant have anti-HLA antibodies

Cited by 46 publications

References 2 publications

Detection and specification of noncomplement binding anti-HLA alloantibodies

Detection and specification of noncomplement binding anti-HLA alloantibodies

Influence ofde novodonor-specific antibody on early renal allograft function recovery

Induction Immunosuppressive Therapy in Kidney Transplantation

Contact Info

Product

Resources

About